Tag Archives: Charles Duncan

Analysts’ Top Healthcare Picks: Novavax (NVAX), Halozyme (HALO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novavax (NVAX – Research Report), Halozyme (HALO – Research Report) and Bluebird Bio (BLUE – Research Report) with bullish sentiments. Novavax (NVAX)

Cantor Fitzgerald Believes ACADIA Pharmaceuticals (NASDAQ: ACAD) Still Has Room to Grow

In a report released today, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $63.00. The company’s shares closed last Thursday at $49.34, close to its 52-week high

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD), Alcon (NYSE: ALC) and Sarepta Therapeutics (NASDAQ: SRPT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACADIA Pharmaceuticals (ACAD – Research Report), Alcon (ALC – Research Report) and Sarepta Therapeutics (SRPT – Research Report). ACADIA Pharmaceuticals (ACAD) In a

Cantor Fitzgerald Keeps Their Hold Rating on Adamas Pharmaceuticals (ADMS)

Cantor Fitzgerald analyst Charles Duncan reiterated a Hold rating on Adamas Pharmaceuticals (ADMS – Research Report) today and set a price target of $7.00. The company’s shares closed last Monday at $4.04, close to its 52-week low of $3.35. According

Cantor Fitzgerald Reiterates Their Buy Rating on Catalyst Pharma (CPRX)

In a report released today, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report), with a price target of $10. The company’s shares opened today at $3.45. Duncan commented: “. We reiterate our

Cytokinetics Inc (CYTK) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Charles Duncan reiterated a Buy rating on Cytokinetics Inc (CYTK – Research Report) today and set a price target of $14. The company’s shares opened today at $8.88. Duncan noted: “. We reiterate our OW rating and